Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status | ESMO
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models | Nature Communications
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer | BioSpace
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy - European Journal of Cancer
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian... | Download Scientific Diagram
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial - Gynecologic Oncology
SGO on Twitter: "Olaparib maintenance therapy improves overall survival in recurrent #ovariancancer - important update of the SOLO2 trial at #ASCO20 #SGOatASCO #gyncsm https://t.co/xX2D6nyErE" / Twitter
PARP inhibitor (olaparib) dramaticalyl extends progression free survival in 1L Maintenance BRCAm ovarian cancer data. Hazard ratio = 0.30. : r/medicine
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
Efficacy of LYNPARZA® (olaparib) from Study 19
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Efficacy of LYNPARZA® (olaparib) for Maintenance in Recurrent Ovarian Cancer
